Clinical characteristics of 136 patients with non‐small cell lung cancer with circulating tumor DNA testing
| Characteristics . | n (%) . |
|---|---|
| Median age (range), yr | 69 (30–95) |
| Sex | |
| Female | 83 (59.8) |
| Male | 53 (40.2) |
| Histology | |
| Adenocarcinoma | 99 (72.8) |
| Squamous | 27 (19.9) |
| NOS | 4 (2.9) |
| Large cell neuroendocrine | 6 (4.4) |
| Smoking status | |
| Minimal/never | 40 (29.4) |
| Current/former | 96 (70.6) |
| Number of prior lines of treatment | |
| 0–1 | 114 (83.8) |
| 2+ | 20 (14.7) |
| N/A | 2 (1.5) |
| Prior radiation therapy | |
| Yes | 55 (40.4) |
| No | 81 (59.6) |
| Stage of disease | |
| III | 25 (18.4) |
| IV | 111 (81.6) |
| Prior History of cancer/treatment | |
| Yes | 32 (23.5) |
| No | 104 (76.5) |
| Presence of EGFR/KRAS mutations | |
| EGFR mutant/wild type | 37/99 |
| KRAS mutant/wild type | 27/109 |
| Characteristics . | n (%) . |
|---|---|
| Median age (range), yr | 69 (30–95) |
| Sex | |
| Female | 83 (59.8) |
| Male | 53 (40.2) |
| Histology | |
| Adenocarcinoma | 99 (72.8) |
| Squamous | 27 (19.9) |
| NOS | 4 (2.9) |
| Large cell neuroendocrine | 6 (4.4) |
| Smoking status | |
| Minimal/never | 40 (29.4) |
| Current/former | 96 (70.6) |
| Number of prior lines of treatment | |
| 0–1 | 114 (83.8) |
| 2+ | 20 (14.7) |
| N/A | 2 (1.5) |
| Prior radiation therapy | |
| Yes | 55 (40.4) |
| No | 81 (59.6) |
| Stage of disease | |
| III | 25 (18.4) |
| IV | 111 (81.6) |
| Prior History of cancer/treatment | |
| Yes | 32 (23.5) |
| No | 104 (76.5) |
| Presence of EGFR/KRAS mutations | |
| EGFR mutant/wild type | 37/99 |
| KRAS mutant/wild type | 27/109 |
Abbreviation: N/A, not applicable; NOS, not otherwise specified.
Clinical characteristics of 136 patients with non‐small cell lung cancer with circulating tumor DNA testing
| Characteristics . | n (%) . |
|---|---|
| Median age (range), yr | 69 (30–95) |
| Sex | |
| Female | 83 (59.8) |
| Male | 53 (40.2) |
| Histology | |
| Adenocarcinoma | 99 (72.8) |
| Squamous | 27 (19.9) |
| NOS | 4 (2.9) |
| Large cell neuroendocrine | 6 (4.4) |
| Smoking status | |
| Minimal/never | 40 (29.4) |
| Current/former | 96 (70.6) |
| Number of prior lines of treatment | |
| 0–1 | 114 (83.8) |
| 2+ | 20 (14.7) |
| N/A | 2 (1.5) |
| Prior radiation therapy | |
| Yes | 55 (40.4) |
| No | 81 (59.6) |
| Stage of disease | |
| III | 25 (18.4) |
| IV | 111 (81.6) |
| Prior History of cancer/treatment | |
| Yes | 32 (23.5) |
| No | 104 (76.5) |
| Presence of EGFR/KRAS mutations | |
| EGFR mutant/wild type | 37/99 |
| KRAS mutant/wild type | 27/109 |
| Characteristics . | n (%) . |
|---|---|
| Median age (range), yr | 69 (30–95) |
| Sex | |
| Female | 83 (59.8) |
| Male | 53 (40.2) |
| Histology | |
| Adenocarcinoma | 99 (72.8) |
| Squamous | 27 (19.9) |
| NOS | 4 (2.9) |
| Large cell neuroendocrine | 6 (4.4) |
| Smoking status | |
| Minimal/never | 40 (29.4) |
| Current/former | 96 (70.6) |
| Number of prior lines of treatment | |
| 0–1 | 114 (83.8) |
| 2+ | 20 (14.7) |
| N/A | 2 (1.5) |
| Prior radiation therapy | |
| Yes | 55 (40.4) |
| No | 81 (59.6) |
| Stage of disease | |
| III | 25 (18.4) |
| IV | 111 (81.6) |
| Prior History of cancer/treatment | |
| Yes | 32 (23.5) |
| No | 104 (76.5) |
| Presence of EGFR/KRAS mutations | |
| EGFR mutant/wild type | 37/99 |
| KRAS mutant/wild type | 27/109 |
Abbreviation: N/A, not applicable; NOS, not otherwise specified.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
